Read more
12:31 PM · 13 May 2020

Gilead Sciences signed a deal for remdesivir.

Gilead Sciences (GILD.US)   announced that it had struck a licensing agreement to produce the antiviral drug remdesivir in 127 countries, not including the US. The company’s will work with five generic drugmakers to produce the potential drug for coronavirus. Among them is Mylan (MYL.US), which is the world's largest producer of generic drugs.


Gilead Sciences (GILD.US)  shares rose 1.96% in pre-market trading. If positive mood persists, then resistance at $86.16 per share may be tested. Source: xStation5

11 February 2026, 8:30 AM

Economic calendar: NFP data and US oil inventory report 💡

10 February 2026, 6:47 PM

Daily summary: Weak US data drags markets down, precious metals under pressure again!

10 February 2026, 6:01 PM

Datadog in Top Form: Record Q4 and Strong Outlook for 2026

10 February 2026, 3:09 PM

US Open: Wall Street rises despite weak retail sales

Join over 2 000 000 XTB Group Clients from around the world
The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits